Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.
Portola Pharmaceuticals' promising antidote for blood thinners has attracted a who's-who of Big Pharma partners, and now the biotech is advancing its reverser of Factor Xa inhibitors to Phase III with the help of Bayer and Johnson & Johnson.
South San Francisco-based Portola Pharmaceuticals has nabbed boasting rights to the FDA's new breakthrough drug designation for andexanet alfa (PRT4445), its Factor Xa inhibitor antidote designed to hit the brake on blood thinners when they turn dangerous.
Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...
The list of biotechs going public grows longer. With public investors warming to biotech IPOs, Portola Pharmaceuticals has proposed a public debut with a relatively sizable maximum aggregate offering amount of $115 million.
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
Portola Pharmaceuticals has signed on to see if its antidote to Factor Xa inhibitors--PRT4445--will help make the blood-thinner Xarelto safer.
Just eight months after Merck ($MRK) dumped its collaboration with Portola Pharmaceuticals on the anti-clotting drug betrixaban, the South San Francisco biotech has rounded up $89 million in new
Soon after taking the helm at Biogen Idec, George Scangos vowed to make the big biotech the "partner of choice" for other promising developers laboring in the same disease fields. This morning Biogen
Merck ($MRK) is writing off the $470 million deal it struck with Portola Pharmaceuticals back in 2009 on betrixaban, an anti-clotting drug once touted as a key asset in the Big Pharma's late-stage